Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

NCT05511844 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

HER2-positive Breast Cancer
HER-2 Protein Overexpression
HER-2 Gene Amplification
HER2 Gene Mutation

Interventions

DRUG: ORM-5029

Sponsor

Orum Therapeutics USA, Inc.